# COAST (NCT03822351)

> Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03822351
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: MedImmune LLC
- Conditions: Stage III Non-small Cell Lung Cancer; Unresectable
- Interventions: Durvalumab + Oleclumab; Durvalumab; Durvalumab + Monalizumab
- Enrollment: 189
- Primary outcome: Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents

## Indexed commentary on COAST so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=coast-nct03822351